PENN AVENUE PARTNERS

Lobbying for ALKERMES, INC. · Pharmaceutical manufacturing and biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $80,000.00 income · posted Apr 2, 2026

Lobbying activity 1

Pharmacy

Regulatory and legislative issues impacting Alkermes. Appropriations.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.